Altimmune Inc (NAS:ALT)
$ 8.57 -0.16 (-1.83%) Market Cap: 609.54 Mil Enterprise Value: 471.93 Mil PE Ratio: 0 PB Ratio: 4.57 GF Score: 30/100

Altimmune Inc Positive Interim Data From ALT-801 Phase 1 Trial In Overweight And Obese Volunteers Conference Call Transcript

Jun 16, 2021 / 12:30PM GMT
Release Date Price: $16.46 (+16.49%)
Operator

Greetings. Welcome to Altimmune, Inc. ALT-801 interim data call. (Operator Instructions) Please note, this conference is being recorded.

At this time, I'll now hand the call over to Stacey Jurchison. Please go ahead, Stacey.

Stacey Jurchison
Altimmune, Inc. - Senior Director of IR and Corporate Communications

Thank you, Rob, and good morning, everyone. Thank you for joining us. Members of the Altimmune team participating on the call today are Vipin Garg, Chief Executive Officer; Scott Harris, Chief Medical Officer; Scot Roberts, Chief Scientific Officer; and Will Brown, Chief Financial Officer.

Please note that we issued a press release this morning, which is the subject of our discussion today. You may find a copy of this press release on the IR section of our website.

Before we begin, I'd like to remind everyone that remarks about future expectations, plans and prospects constitute forward-looking statements for purpose of safe harbor provisions under the Private Securities Litigation Reform Act of 1995.

Altimmune

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot